ACADIA Pharmaceuticals Inc.
NASDAQ:ACADBiotechnology
-$0.13 today
- Market cap
- $3.08B
- Beta
- 0.83
- P/E (TTM)
- 9.7
- EPS (TTM)
- $2.20
Volume 1.89M
Average 1.66M
ACAD Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
ACADIA Pharmaceuticals Inc.NASDAQ: ACAD
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation growth accelerates
Q2 FY2026 stock-based compensation of $31.64M rose 120.6% year over year, ahead of the -4.5% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 115.3% from the prior quarter.
Context
- Stock-based compensation amounted to 0.0% of revenue in FY2025, down 7.0 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +120.6% holds above the trailing-twelve-month pace of -4.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 67.05M | +0.9% |
| FY2023 | 2023-12-31 | 66.42M | -2.6% |
| FY2022 | 2022-12-31 | 68.2M | +7.2% |
| FY2021 | 2021-12-31 | 63.62M | — |
Stock-Based Compensation vs competitors
How ACAD compares with its peers on the latest reported figures
- ACAD's LTM Jun 2026 stock-based compensation of $59.52M is the 2nd largest of the 11 companies compared; the peer median is $10.95M.
- Its year-over-year change of -4.5% is the 5th highest of 10, against a peer median of -5.4%.
- Stock-based compensation amounts to 5.2% of revenue for ACAD, versus a peer median of 12.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $96.42M | +5.3% | +35.5% | 12.4% | |
| LTM Jun 2026 | $59.52M | -4.5% | — | 5.2% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $27.96M | -33.3% | +53.3% | — |
| LTM Sep 2026 | $26.2M | -19.6% | +5.9% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $21.78M | +70.4% | +213.9% | 108.9% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $11.29M | +31.2% | +73.3% | — |
| LTM Dec 2025 | $10.6M | +15.1% | -14.3% | — | |
| LTM Mar 2026 | $9.07M | -23.3% | -16.5% | 4.2% | |
| LTM Mar 2026 | $7.02M | -5.4% | +66.3% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $1.37M | — | — | — |
| LTM Mar 2026 | $125K | -78.0% | — | — | |
| Peer median (excluding ACAD) | $10.95M | -5.4% | +44.4% | 12.4% | |
Competitors are the stored peer set for ACAD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (167.87M) | (215.98M) | (61.29M) | 226.45M | 391M |
| Depreciation & Amortization | 3.34M | 2.03M | 5.55M | 15.88M | 11.76M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (249.88M) |
| Stock-Based Compensation | 63.62M | 68.2M | 66.42M | 67.05M | 0 |
| Change in Working Capital | (24.82M) | 37.99M | 18.13M | 4.16M | (89.76M) |
| Accounts Receivables | (16.12M) | 2.26M | (39.27M) | (2.35M) | (43.54M) |
| Inventory | (4.21M) | 2.42M | (28.81M) | (49.55M) | (18.2M) |
| Accounts Payables | (1.62M) | 5.87M | 4.8M | (1.35M) | (5.29M) |
| Other Working Capital | (2.88M) | 27.44M | 81.41M | 57.4M | (22.73M) |
| Other Non-Cash Items | 75K | (6.28M) | (12.12M) | (155.82M) | 46.71M |
| Operating Cash Flow | (125.66M) | (114.04M) | 16.7M | 157.72M | 109.84M |
| Capital Expenditures | (1.12M) | 0 | (40.05M) | (523K) | (4.69M) |
| Acquisitions (Net) | 69.98M | 0 | (32.05M) | 0 | 0 |
| Purchases of Investments | (492.8M) | (363.17M) | (369.99M) | (505.1M) | (692.57M) |
| Sales of Investments | 422.82M | 436.42M | 442.03M | 328.57M | 493.53M |
| Other Investing Activities | (69.98M) | 0 | 32.05M | 146.52M | 0 |
| Investing Cash Flow | (71.1M) | 73.24M | 32M | (30.54M) | (302.56M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 18.16M | 8.2M | 25.13M | 6.85M | 49.88M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 18.16M | 8.2M | 25.13M | 6.85M | 49.88M |
| Effect of Forex Changes | 7K | 6K | (18K) | (94K) | 951K |
| Net Change in Cash | (178.59M) | (32.59M) | 73.81M | 133.93M | (141.89M) |
| Free Cash Flow | (126.78M) | (114.04M) | (23.35M) | 157.2M | 105.15M |
ACADIA Pharmaceuticals Inc.
NASDAQ:ACAD
Intrinsic Alpha fair value
Locked
Current Price
$17.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.